期刊文献+

Experimental study on the photodynamic treatment of choroidal neovasculization with nanophthaloc-yanine photosensitizer 被引量:1

Experimental study on the photodynamic treatment of choroidal neovasculization with nanophthaloc-yanine photosensitizer
下载PDF
导出
摘要 AIM: To investigate the therapeutic effects of nanophthalocyanine photosensitizers on an experimental rat choroidal neovescularization (CNV) model, as well as to evaluate the cytotoxicity of which on human retinal pigment epithelia (HRPE) and human retinal endothelial cells (HRECs). METHODS: Two types of photosensitizers, G(1)-ZnPc(COOH)(8) and G(1)-ZnPc (COOH)(8)/m respectively, were administrated for photodynamic therapy (PDT) after a successful establishment of CNV model on Brown-Norway (BN) rats via fundus photocoagulation. The therapeutic effects of the two drugs were assessed through optical coherence tomography (OCT), fluorescein fundus angiography (FFA) and transmission electron microscopy (TEM). For cytotoxicity tests, cell counting kit-8 (CCK-8) assays and changes of mitochondrial transmembrane potential (Delta psi m) were conducted on HRPE and HRECs after initial uptake of the two drugs. RESULTS: Both photosensitizers demonstrated an improvement of vascular leakage and closure of CNV 1 week after PDT as confirmed by fundus image, OCT, FFA and TEM. Two weeks after PDT, G(1)-ZnPc (COOH)(8)/m showed a better CNV closure effect versus G(1)-ZnPc(COON)(8)(P<0.05). A significant difference (P<0.01) was found in uptake of the two drugs in HRPE and HRECs, with no difference between the drugs(P>0.05). Both photosensitizers showed cytotoxicity on HRPE, but G(1)-ZnPc(COOH)(8)/m induced a lower cell viability. CONCLUSION: G(1)-ZnPc (COOH)(8)/m mediated PDT is better than G(1)-ZnPc (COOH)(8) in CNV closure and also have the advantage of fast metabolism leading to less side effect. AIM: To investigate the therapeutic effects of nanophthalocyanine photosensitizers on an experimental rat choroidal neovescularization (CNV) model, as well as to evaluate the cytotoxicity of which on human retinal pigment epithelia (HRPE) and human retinal endothelial cells (HRECs). METHODS: Two types of photosensitizers, G(1)-ZnPc(COOH)(8) and G(1)-ZnPc (COOH)(8)/m respectively, were administrated for photodynamic therapy (PDT) after a successful establishment of CNV model on Brown-Norway (BN) rats via fundus photocoagulation. The therapeutic effects of the two drugs were assessed through optical coherence tomography (OCT), fluorescein fundus angiography (FFA) and transmission electron microscopy (TEM). For cytotoxicity tests, cell counting kit-8 (CCK-8) assays and changes of mitochondrial transmembrane potential (Delta psi m) were conducted on HRPE and HRECs after initial uptake of the two drugs. RESULTS: Both photosensitizers demonstrated an improvement of vascular leakage and closure of CNV 1 week after PDT as confirmed by fundus image, OCT, FFA and TEM. Two weeks after PDT, G(1)-ZnPc (COOH)(8)/m showed a better CNV closure effect versus G(1)-ZnPc(COON)(8)(P<0.05). A significant difference (P<0.01) was found in uptake of the two drugs in HRPE and HRECs, with no difference between the drugs(P>0.05). Both photosensitizers showed cytotoxicity on HRPE, but G(1)-ZnPc(COOH)(8)/m induced a lower cell viability. CONCLUSION: G(1)-ZnPc (COOH)(8)/m mediated PDT is better than G(1)-ZnPc (COOH)(8) in CNV closure and also have the advantage of fast metabolism leading to less side effect.
出处 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2011年第6期575-581,共7页 国际眼科杂志(英文版)
基金 National Natural Science Foundation of China(No.81070715) Innovative Platform Foundation of Fujian Province, China (No.2010Y2003) Key Research Projects Foundation of Fujian Province,China (No.2008Y0040)
关键词 PHTHALOCYANINE CARRIER nanoparticles photodynamic treatment retina pigment epithelial cells choroidal neovascularization phthalocyanine carrier nanoparticles photodynamic treatment retina pigment epithelial cells choroidal neovascularization
  • 相关文献

参考文献24

  • 1李步洪,谢树森.功能型光敏剂的研究进展[J].中国激光医学杂志,2007,16(3):179-185. 被引量:13
  • 2Klein R,Klein BE,Tomany SC,Meuer SM,Huang GH.Ten-year incidence and progression of age-related maculopathy:The Beaver Dam eye study. Ophthalmology . 2002
  • 3Stolba U,Krebs I,Lamar PD,Aggermann T,Gruber D,Binder S. British Journal of Ophthalmology . 2006
  • 4Kroll P,Meyer CH.Which treatment is best for which AMD patient?. British Journal of Ophthalmology . 2006
  • 5Heier JS,Boyer DS,Ciulla TA,Ferrone PJ,Jumper JM,Gentile RC,Kotlovker D,Chung CY,Kim RY.Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration:year 1 results of the FOCUS study. Archives of Ophthalmology . 2006
  • 6Liggett PE,Colina J,Chaudhry NA,Tom D,Haffner G.Triple therapy ofintravitreal triamcinolone,photodynamic therapy,and pegaptanib sodium for choroidal neovascularization. American Journal of Ophthalmology . 2006
  • 7Xu DY.Research and development of photodynamic therapy photosensitizer in China. Photodiag Photodyna Ther . 2007
  • 8Hwaley AE,Dvais SS,Illum L.Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adavnaced drug delivery review . 1995
  • 9Julinao RL.Factors affecting the clearance kinetics and tissue with verteporfin for choroidal neovaseularization caused by agedisrtibution of liposomes, micorspheres and emulsions. Arch OPhhtalmol . 1999
  • 10Duncna R.Drug targeting: where are we now and where are we neovascularization in age related macular degeneration with vergoing?. DurgTarg . 1997

二级参考文献49

  • 1Dougherty TJ,Gomer CJ,Henderson BW,et al.Photodynamic therapy[J].J Natl Cancer Inst,1998,90:889-905.
  • 2MacDonald IJ,Dougherty TJ.Basic principles of photodynamic therapy[J].J Porphyrins Phthalocyanines,2001,5:105-129.
  • 3Jarvi M,Niedre M,Patterson M,et al.Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy:current status,challenges and future prospects[J].Photochem Photobiol,2006,82:1198-1210.
  • 4Dolmans DE,Fukumura D,Jain RK.Photodynamic therapy for cancer[J].Nat Rev Cancer,2003,3:380-387.
  • 5Moan J,Peng Q.An outline of the hundred-year history of PDT[J].Anticancer Res,2003,23:3591-3600.
  • 6Dougherty TJ.An update on photodynamic therapy applications[J].J Clin Laser Med Surg,2002,20,3-7.
  • 7Allison RR,Bagnato VS,Cuenca R,et al.The future of photodynamic therapy in oncology[J].Future Oncol,2006,2:53-71.
  • 8Pervaiz S,Olivo M.Art and science of photodynamic therapy[J].Clin Exp Pharmacol Physiol,2006,33:551-556.
  • 9Huang Z.A review of progress in clinical photodynamic therapy[J].Technol Cancer Res Treat,2005,4:283-293.
  • 10Bakalova R,Ohba H,Zhelev Z,et al.Quantum dots as photosensitizers[J].Nat Biotechnol,2004,22:1360-1361.

共引文献16

同被引文献7

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部